리포솜형 독소루비신 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Liposomal Doxorubicin Market

The future of the global liposomal doxorubicin market looks promising with opportunities in the breast cancer, ovarian cancer, AIDS-related kaposi's sarcoma, and multiple myeloma markets. The global liposomal doxorubicin market is expected to reach an estimated $2.7 billion by 2035 from $1.6 billion in 2027 with a CAGR of 7.4% from 2027 to 2035. The major drivers for this market are the increasing adoption of targeted cancer therapies, the rising demand for advanced chemotherapy treatments, and the growing focus on drug delivery efficiency.

• Lucintel forecasts that, within the product category, lipodox is expected to witness the highest growth over the forecast period due to less expensive than branded alternatives.
• Within the application category, breast cancer is expected to witness the highest growth over the forecast period due to increasing breast cancer cases.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to combined high prevalence of cancer and a well-developed oncology service infrastructure.

Emerging Trends in Liposomal Doxorubicin Market

The liposomal doxorubicin market is expected to grow in the next few years as new oncology indications and more targeted, safe, chemotherapy delivery methods are developed. Between 2025 and 2027, more patients are expected to be diagnosed with cancer, and Patents will expire, resulting in increased competition. Additionally, advancements in manufacturing will occur. Lucintel expects that, by this time, Cardiac safety would be the most important consideration when deciding on the treatment of cancer.

• Targeted Oncology: Advances in oncology are expected to result in new liposomal doxorubicin products that have tumour-selective release. Products with prolonged release times and reduced cardiac toxicity will be prioritized by the medical community.
• Combination Therapy: During this same time period, it is expected that liposomal doxorubicin will be combined with other targeted therapies, immunotherapies and/or other chemo-therapies. Currently, the majority of clinical trials that combine liposomal doxorubicin with other agents are being conducted in the treatment of multiple myeloma. It is expected that, by 2026, several of these combination therapies would be approved and reimbursed. After 2026, it is expected that additional combinations of liposomal doxorubicin will be approved and integrated into clinical practice.
• Biosimilar and Generic Pressure: With several biosimilar liposomal doxorubicin products expected to enter the market in the next few years, the price of these products is expected to decrease significantly in the markets that they penetrate. As a result, providers would be required to make important value-based decisions as to which liposomal doxorubicin products to use based upon the outcomes expected.
• Modernization of Manufacturing: Producers of liposomal formulations are enhancing their manufacturing processes to meet the challenges of liposome encapsulation, and commercial products are aimed at achieving a drug encapsulation efficiency of 90% or more.
• Newer Customer Base (Geographic Market Diversification): As drug shortages of cancer products persist, customers are seeking alternate suppliers. In 2024, the American Society of Health-System Pharmacists (ASHP) reported 323 active drug shortages in the U.S. Market access, pricing and inventory levels will be determined by the degrees of regional-capacity expansions in Europe and Asia-Pacific between 2020 and 2030.

In the coming years, we expect the market for liposomal doxorubicin to experience more lateral than vertical growth. Liposomal formulations of other anti-cancer drugs are expected to enter the market, and we expect they will be priced lower than liposomal doxorubicin. To sustain their positions in the market, liposomal doxorubicin manufacturers will need to ensure the uninterrupted and sterile supply of their product, and if possible, combine their product with other anti-cancer drugs.

Recent Developments in the Liposomal Doxorubicin Market

Competition for the liposomal doxorubicin market will increase during the period 2025-2027 as a result of the entry of generic players, positive clinical trials for new anti-cancer drugs, and growing demand for lower-toxicity chemotherapy drugs. It is expected that in the foreseeable future, new indications will be granted for liposomal doxorubicin. Lucintel expects that cancer treatment will increase in the coming years, and with that, hospital protocols will change to include the use of liposomal doxorubicin and other antibody-drug conjugates.

• New Generics: In 2025, the FDA is expected to grant approval for a doxorubicin liposome injection, 20 mg/ml and 50 mg/ml, resulting in more suppliers and hopefully no more drug shortages. It is, however, expected that in the coming years, reimbursement will drive payment for liposomal doxorubicin by hospitals.
• Contract Manufacturing: Additionally, in 2025, a contract manufacturer in Europe announced it will build a new facility to produce sterile drug products, which will increase the supply of liposomal drugs in the European market.
• Combination Therapy Trials: Clinical development of pegylated liposomal doxorubicin (PLD) is occurring with immunotherapies and other agents. A phase 2 trial started in 2025, and includes 120 patients. This trial shows an emerging interest in combinations for treatments of cancers of the ovary, breast and blood.
• Specialty Oncology Partnerships: Other companies are licensing and/or distributing liposomal doxorubicin (LIPDOX) in areas outside of their jurisdiction. The 2025 LIPDOX contract involved Southeast Asia. Specialty partners can make LIPDOX/PLD available in areas where it is license/distributed, and shift the responsibility for registration and commercialization to these partners.
• Formulation Innovation: Competing formulations of doxorubicin with improved pharmacokinetics are in various stages of development. If improved safety is demonstrated, enhanced formulations may command a price premium and displace first generation pegylated formulations.

It is expected that during the next 3-5 years, the main drivers of growth for LIPDOX/PLD will be differentiation, and reliable and consistent supply of a sterile product, as opposed to changes in cancer prevalence. LIPDOX/PLD will remain expensive due to its biological and chemical complexity. Payer organizations will primarily determine the markets in which the product is available. Improved combinations and/or regulatory strategy will allow suppliers to maintain or increase market share. Undifferentiated suppliers will lose share through price cutting.

Strategic Growth Opportunities in the Liposomal Doxorubicin Market

Commercial potential for liposomal doxorubicin will increase during the 2024-2026 period with the change in the focus of oncology to targeted, out-patient, and less toxic cancer therapy. Lucintel's project interest covers specialty-generic, combination, and access pharmaceutical therapies. Positive trend in cancer incidence, along with clarity in the regulatory environment, has led to increased interest in previously unstudied indications.

• Combination Oncology Regimens: The use of liposomal doxorubicin in combination with other drugs to form a combination oncology regimen will create a value market during the 2024-2028 period, particularly in cases where the formation of cumulative cardiac toxicity potential limits the use of other anthracycline drugs. During the 2025-2027 period, combination oncology regimens will be the focus of pharmaceutical research. -
• Hematologic Malignancies: Use of liposomal doxorubicin will increase in hematologic malignancies and multiple myeloma. The National Cancer Institute also listed liposomal doxorubicin for treatment of other hematologic malignancies. The increased use will be for patients who have undergone previous treatment.
• Access To Emerging Markets: Localized fill-finish, price competition from biosimilars, and government tenders can provide access to more affordable markets including Asia, Latin America and the Middle East. The WHO Model List of Essential Medicines (March 2025) included 22 cancer medicines, promoting the sourcing of affordable cancer medicines. Price-access strategies will be more effective in increasing volume of sales as compared to strategy focused on charging a premium.
• New Liposomal Technologies: Over the next several years, premium pricing may be justified for oncology products with improved tumour accumulation and/or reduced hand foot syndrome. In April 2025, there were a number of clinical trials for the use of pegylated liposomal doxorubicin at a dose of 40 mg/m2. In the same time frame, sponsors of oncology products may be able to differentiate their products based on liposomal formulations.
• Outpatient and Home-based Cancer Treatment: There is a trend to administer cancer medicinal products through the outpatient and/or ambulatory route. Such products would require an extended and/or continuous infusion. In addition, the sponsor of the product would need to ensure a stable supply of the product. In May 2025, the Centers for Medicare and Medicaid Services (CMS) of the U.S. continued to reimburse certain outpatient oncology services. There will be a focus on reducing total cost of treatment and increasing efficiency of medical personnel.

Manufacturers are advised to focus on the inter-section of performance, access and evidence to improve their returns. It is particularly important for manufacturers to focus on local and regional regulations to improve access and reliability of supply of their products. The strongest returns will be from products that address toxicity of cancer medicinal products and facilitate outpatient treatments.

Liposomal Doxorubicin Market Drivers and Challenges

Liposomal doxorubicin market trends and factors include local technology and oncology industry development, the economy, and regulations. Increasing demand for cancer treatments and improvement in cancer drug delivery methods created market opportunities, but challenged it with price competition and restrictions. According to Lucintel, market trends will be affected by ongoing economic and technological developments in the health care industry of both developed and developing countries.

The factors responsible for driving this market include:

• Demand from Patients: Increased cancer cases have created an increasing demand for liposomal doxorubicin for the treatment of cancers such as breast, ovary and hematological malignancies. Compared to other doxorubicin based treatments, liposomal doxorubicin has fewer patient toxicities and is well accepted by oncologists. The American Cancer Society estimated 2,092,870 new cancer cases in the US for 2025. The 3 to 5 year target aging population along with greater accessibility of cancer treatment is expected to create continuous demand for liposomal doxorubicin.
• Delivery Technology: Research advances in oncology promote the development of next-generation delivery systems. The past year (2025) has seen continued investment in nanotechnology-based delivery systems for oncology. Advances in the manufacture of delivery systems are expected to result in improved formulations with enhanced performance. Development in this area may result in delivery systems that target tumour cells and/or tissue. The formulation of combination therapies and improved consistency of formulations may allow tumour treatment to extend beyond the oncology setting to include the treatment of other cancers. The next 5 years may see an increasing number of oncology products entering the market.
• Regulatory Support: The introduction and revision of guidelines by regulatory agencies facilitates the development and introduction of new oncology products. Guidelines that promote the development of targeted therapies, e.g. therapy for rare cancers, further encourage and facilitate the development of new cancer products. In 2025, guidelines emphasized the need for the development of safe and effective cancer products and the importance of the comparability of drug products.
• Healthcare Investment: Increased spending in cancer care has led to development of cancer-specific hospitals and infusion centres and improved diagnostic facilities. This has improved the access to cancer medicines including novel, advanced and injectable therapies. This trend is notable in Asia-Pacific, Latin America and the Middle East. Stronger country-level cancer control strategies focused on improving access and timeliness of cancer care have been adopted. In the next 3 to 5 years, there will be improved infrastructure to offer cancer care, especially in low- and middle-income countries (LMICs). Uniformity of cancer care will, however, remain unacceptable due to lack of cancer-specific workforce and health financing.
• Manufacturing Improvement: Reliable and improved supply of medicines has been limited due to numerous challenges faced by pharmaceutical companies. Aseptic processing of medicinal products, including liposomal products, requires very stringent processes to ensure the integrity of the loaded drug and its release. Injectable products, by nature, require very stringent processes to ensure the end-product is free from any contaminants. Continuous improvements in processes and integration of automation in manufacturing will enhance reliability of injectable medicinal products and reduce their costs. In the next 3 to 5 years, this will result in improved supply and reduced regulatory and health care system challenges.

The challenges facing this market include:

• Higher Development Costs: The development of Liposomal Doxorubicin requires expensive equipment and precise production and control processes. Evidence shows that manufacturing Liposomal Doxorubicin poses a challenge for emerging market and generics companies. In August 2025, pharma companies continued to invest in the development of complex injectable products because traditional bioequivalence tests do not evaluate equivalence. In the next 3 to 5 years, only a few companies will be able to manufacture Liposomal Doxorubicin because of the high costs. The rest of the companies will use strategies like manufacturing under a license or manufacturing it for other companies.
• Pricing and Reimbursement: In October 2025, certain healthcare systems had ongoing initiatives to negotiate the price of cancer drugs and establish value-based contracts. Other systems contracted suppliers of cancer drugs to achieve better outcomes for patients. The suppliers that focused on value had a competitive edge. In the next 3 to 5 years, it is expected that value-based contracts will be negotiated for most of the cancer drugs and manufacturers will focus on offering added value by means of improving the reliability of the supply, offering patient support services and creating combination drugs.
• Supply Chain and Quality Risk: The production of liposomal products requires specialized ingredients and facilities, as well as validated packaging and storage. Disruptions at any point in the process may result in a lack of treatment options for patients. In May 2025, disruptions in global pharmaceutical supply chains negatively impacted the supply of complex injectables. It is anticipated that in the next three to five years, in order to minimize supply chain risks, manufacturers would employ a range of strategies, including the use of multiple suppliers, local manufacturing, and enhanced inventory and quality controls. While the use of these strategies may increase the cost of products, it is anticipated that liposomal doxorubicin and similar products would remain in high demand and gain greater market penetration in both established and new/emerging markets.

Although manufacturing and market constraints are expected to impact the rate of market penetration, the net effect of these constraints would likely be positive and strengthen market positioning. The relative positioning of market participants would likely depend on the outcome of concurrent efforts to develop and commercialize comparable products. It is to be expected that market participants would focus efforts and investments on the improvement of value (quality) and growth (scale) to gain market position and sustainability.

List of Liposomal Doxorubicin Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies liposomal doxorubicin market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the liposomal doxorubicin market companies profiled in this report include-

• Sun Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Cipla
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
• Lupin
• Cadila Pharmaceuticals
• SRS Life Sciences
• GSK plc
• Pfizer Inc.

Liposomal Doxorubicin Market by Segment

The study includes a forecast for the global liposomal doxorubicin market by product, distribution channel, application, and region.

Liposomal Doxorubicin Market by Product [Value ($B) from 2019 to 2035]:

• Doxil/Caelyx
• Lipodox
• Myocet
• Others

Liposomal Doxorubicin Market by Distribution Channel [Value ($B) from 2019 to 2035]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Liposomal Doxorubicin Market by Application [Value ($B) from 2019 to 2035]:

• Breast Cancer
• Ovarian Cancer
• AIDS-related Kaposi's Sarcoma
• Multiple Myeloma
• Others

Liposomal Doxorubicin Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Liposomal Doxorubicin Market

Between 2025 and 2027, increased generic competition and more stringent supply chain management by manufacturers will be the main trends in the liposomal doxorubicin market. Agencies such as the Food and Drug Administration (FDA) will look to ensure manufacture and distribution of safe and effective liposomal doxorubicin. With this situation, Lucintel expects the trends in the liposomal doxorubicin market will remain the same.

• United States: United States, the liposomal doxorubicin market will favour manufacturers who can secure distribution to hospitals from reliable and consistent sources. Manufacturing to higher standards set by the FDA along with increased competition will help alleviate the drug shortages reported by the FDA. In March 2025, the FDA reported 323 drug shortages.
• China: China will also follow similar trends as local manufacturers strengthen their capabilities to produce more advanced injectable pharmaceuticals. Along with this trend, there will be increased demand and supply of liposomal doxorubicin in China.
• Germany: Leading German pharmaceutical manufacturers have invested in high-containment and aseptic processes to manufacture oncology medicines. In February 2025, the EMA announced 104 medicinal products authorized for marketing, including advanced therapies. German pharmaceutical companies are expected to continue investing to capitalize on the opportunities created by the centralized nature of EMA processes and requirements.
• India: India's central and state governments have also launched production-linked incentive and similar schemes focused on the pharmaceutical sector. Further, the government announced an increase in the budget for its pharma PLI scheme. This is expected to promote the local production of complex APIs and pharmaceutical intermediates, and finished forms of oncology medicines. Moreover, in line with the 'Make in India' initiative, the government introduced a series of measures to improve the production and supply of pharmaceutical products.
• Japan: Japan's regulatory body and the pharmaceutical industry have taken a series of measures to ensure an adequate supply of safe and effective injectable medicines. As Japan's population ages and is at a greater risk of developing cancer, there is increased demand for cancer medicines. Alternative liposomal doxorubicin is anticipated to follow a similar trend.

Features of the Global Liposomal Doxorubicin Market

• Market Size Estimates: liposomal doxorubicin market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: liposomal doxorubicin market size by product, distribution channel, application, and region in terms of value ($B).
• Regional Analysis: liposomal doxorubicin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different products, distribution channels, applications, and regions for the liposomal doxorubicin market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the liposomal doxorubicin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the liposomal doxorubicin market by product (doxil/caelyx, lipodox, myocet, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (breast cancer, ovarian cancer, aids-related kaposi's sarcoma, multiple myeloma, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Liposomal Doxorubicin Market by Product

• 4.1 Overview
• 4.2 Attractiveness Analysis by Product
• 4.3 Doxil/Caelyx : Trends and Forecast 2019 to 2035
• 4.4 Lipodox : Trends and Forecast 2019 to 2035
• 4.5 Myocet : Trends and Forecast 2019 to 2035
• 4.6 Others : Trends and Forecast 2019 to 2035

5. Global Liposomal Doxorubicin Market by Distribution Channel

• 5.1 Overview
• 5.2 Attractiveness Analysis by Distribution Channel
• 5.3 Hospital Pharmacies : Trends and Forecast 2019 to 2035
• 5.4 Retail Pharmacies : Trends and Forecast 2019 to 2035
• 5.5 Online Pharmacies : Trends and Forecast 2019 to 2035

6. Global Liposomal Doxorubicin Market by Application

• 6.1 Overview
• 6.2 Attractiveness Analysis by Application
• 6.3 Breast Cancer : Trends and Forecast 2019 to 2035
• 6.4 Ovarian Cancer : Trends and Forecast 2019 to 2035
• 6.5 AIDS-related Kaposi's Sarcoma : Trends and Forecast 2019 to 2035
• 6.6 Multiple Myeloma : Trends and Forecast 2019 to 2035
• 6.7 Others : Trends and Forecast 2019 to 2035

7. Regional Analysis

• 7.1 Overview
• 7.2 Global Liposomal Doxorubicin Market by Region

8. North American Liposomal Doxorubicin Market

• 8.1 Overview
• 8.2 North American Liposomal Doxorubicin Market by Product
• 8.3 North American Liposomal Doxorubicin Market by Application
• 8.4 The United States Liposomal Doxorubicin Market
• 8.5 Canadian Liposomal Doxorubicin Market
• 8.6 Mexican Liposomal Doxorubicin Market

9. European Liposomal Doxorubicin Market

• 9.1 Overview
• 9.2 European Liposomal Doxorubicin Market by Product
• 9.3 European Liposomal Doxorubicin Market by Application
• 9.4 German Liposomal Doxorubicin Market
• 9.5 French Liposomal Doxorubicin Market
• 9.6 Italian Liposomal Doxorubicin Market
• 9.7 Spanish Liposomal Doxorubicin Market
• 9.8 The United Kingdom Liposomal Doxorubicin Market

10. APAC Liposomal Doxorubicin Market

• 10.1 Overview
• 10.2 APAC Liposomal Doxorubicin Market by Product
• 10.3 APAC Liposomal Doxorubicin Market by Application
• 10.4 Chinese Liposomal Doxorubicin Market
• 10.5 Indian Liposomal Doxorubicin Market
• 10.6 Japanese Liposomal Doxorubicin Market
• 10.7 South Korean Liposomal Doxorubicin Market
• 10.8 Indonesian Liposomal Doxorubicin Market

11. ROW Liposomal Doxorubicin Market

• 11.1 Overview
• 11.2 ROW Liposomal Doxorubicin Market by Product
• 11.3 ROW Liposomal Doxorubicin Market by Application
• 11.4 Middle Eastern Liposomal Doxorubicin Market
• 11.5 South American Liposomal Doxorubicin Market
• 11.6 African Liposomal Doxorubicin Market

12. Competitor Analysis

• 12.1 Product Portfolio Analysis
• 12.2 Operational Integration
• 12.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

• 13.1 Value Chain Analysis
• 13.2 Growth Opportunity Analysis
  • 13.2.1 Growth Opportunity by Product
  • 13.2.2 Growth Opportunity by Distribution Channel
  • 13.2.3 Growth Opportunity by Application
• 13.3 Emerging Trends in the Global Liposomal Doxorubicin Market
• 13.4 Strategic Analysis
  • 13.4.1 New Product Development
  • 13.4.2 Certification and Licensing
  • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

• 14.1 Competitive Analysis Overview
• 14.2 Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.3 Johnson & Johnson Services, Inc.
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.4 Merck & Co., Inc.
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.5 Cipla
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.6 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.7 Lupin
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.8 Cadila Pharmaceuticals
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.9 SRS Life Sciences
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.10 GSK plc
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.11 Pfizer Inc.
  • Company Overview
  • Liposomal Doxorubicin Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

15. Appendix

• 15.1 List of Figures
• 15.2 List of Tables
• 15.3 Research Methodology
• 15.4 Disclaimer
• 15.5 Copyright
• 15.6 Abbreviations and Technical Units
• 15.7 About Us
• 15.8 Contact Us